BETA

A novel family of anti-inflammatory drugs modifying the MEK→ ERK→ AP-1 signalling axis in cells and its role in inflammation.

The MEK/ERK/AP-1 signaling pathway is a critically important pathway that interprets inflammatory signals reaching a cell and turns those signals into gene expression driving both acute and chronic inflammation.

BETA drugs are distinguished by an ability to bind to select MEK and ERK proteins that delivers a unique range of anti-inflammatory and immunotherapy effects.

A further distinguishing feature of BETA platform drugs is their ready ability to cross the blood-brain barrier, giving them a highly-prized ability to treat neuroinflammatory conditions.

Therapeutic Targets

Neuro-inflammatory conditions of the CNS, eye (wet AMD) and peripheral nerves. Cancer and cardiac reperfusion injury.

BETA Pipeline Drugs

• BETA-TT8 Eyedropper Gel
• BETA-TT8 Oral
• BETA-TT17 Cancer